A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease

Conclusions There was no increased risk of cancer overall in individuals with IBD compared to IBD-free individuals. Consistent with previous findings, a reduction in cancer risk was observed in IBD patients using aminosalicylates, with a substantial reduction in prostate cancer risk. Further large-scale studies examining the relationship between IBD therapy and cancer risk appear to be warranted.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research